The FDA approved a new drug last month to help prevent delayed-phase nausea and vomiting in patients undergoing cancer chemotherapy.
Rolapitant, marketed as Varubi, was approved for use by adults in combination with other antiemetic drugs (http://1.usa.gov/1EBmeA2). Nausea and vomiting are common among patients with cancer who receive chemotherapy, sometimes persisting for days following treatment. Delayed-phase nausea and vomiting is defined as occurring from 24 hours to up to 120 hours after the start of chemotherapy.
Voelker R. Easing Cancer Chemotherapy Effects. JAMA. 2015;314(15):1554. doi:10.1001/jama.2015.13011
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: